Do analysts recommend LNSR or TMDIF?

LENSAR currently has a consensus price target of $10.00, suggesting a potential upside of 78.57%. Given LENSAR's stronger consensus rating and higher possible upside, analysts plainly believe LENSAR is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LNSR or TMDIF more profitable?

LENSAR has a net margin of 50.94% compared to Titan Medical's net margin of 0.00%. Titan Medical's return on equity of -82.31% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 50.94% -183.19% 42.26% Titan Medical N/A -82.31% -51.47%

Do analysts recommend DXR or TMDIF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, DXR or TMDIF?

Titan Medical has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor $10.30M 5.92 N/A N/A N/A Titan Medical $17.63M 0.74 $6.95M $0.05 2.30

Is DXR or TMDIF more profitable?

Daxor's return on equity of 0.00% beat Titan Medical's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Titan Medical N/A -82.31% -51.47%

Do analysts rate NYXH or TMDIF?

Nyxoah presently has a consensus target price of $5.96, indicating a potential upside of 325.89%. Given Nyxoah's stronger consensus rating and higher probable upside, equities analysts plainly believe Nyxoah is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nyxoah 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, NYXH or TMDIF?

Titan Medical has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $15.33M 3.54 -$101.92M -$2.48 N/A Titan Medical $17.63M 0.74 $6.95M $0.05 2.30

Is NYXH or TMDIF more profitable?

Titan Medical has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. Titan Medical's return on equity of -82.31% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% Titan Medical N/A -82.31% -51.47%

Do analysts rate LUNG or TMDIF?

Pulmonx presently has a consensus target price of $5.58, suggesting a potential upside of 377.21%. Given Pulmonx's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pulmonx is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmonx 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LUNG or TMDIF more profitable?

Titan Medical has a net margin of 0.00% compared to Pulmonx's net margin of -60.09%. Titan Medical's return on equity of -82.31% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% Titan Medical N/A -82.31% -51.47%

Do analysts prefer TMDIF or MDAI?

Spectral AI has a consensus target price of $4.00, suggesting a potential upside of 143.90%. Given Spectral AI's stronger consensus rating and higher possible upside, analysts clearly believe Spectral AI is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spectral AI 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Titan Medical (TMDIF) Competitors

$0.12 -0.02 (-13.01%)

As of 07/24/2026

Compare

TMDIF vs. LNSR, DXR, NYXH, LUNG, and MDAI

Should you buy Titan Medical stock or one of its competitors? MarketBeat compares Titan Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Titan Medical include LENSAR (LNSR), Daxor (DXR), Nyxoah (NYXH), Pulmonx (LUNG), and Spectral AI (MDAI). These companies are all part of the "medical equipment" industry.

How does Titan Medical compare to LENSAR?

LENSAR (NASDAQ:LNSR) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

LENSAR has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

In the previous week, LENSAR had 2 more articles in the media than Titan Medical. MarketBeat recorded 2 mentions for LENSAR and 0 mentions for Titan Medical. LENSAR's average media sentiment score of 0.93 beat Titan Medical's score of 0.00 indicating that LENSAR is being referred to more favorably in the media.

Company	Overall Sentiment
LENSAR	Positive
Titan Medical	Neutral

LENSAR currently has a consensus price target of $10.00, suggesting a potential upside of 78.57%. Given LENSAR's stronger consensus rating and higher possible upside, analysts plainly believe LENSAR is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Titan Medical has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$57.70M	1.19	-$34.28M	-$0.58	N/A
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30

40.2% of LENSAR shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LENSAR has a net margin of 50.94% compared to Titan Medical's net margin of 0.00%. Titan Medical's return on equity of -82.31% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
Titan Medical	N/A	-82.31%	-51.47%

Summary

LENSAR beats Titan Medical on 11 of the 16 factors compared between the two stocks.

How does Titan Medical compare to Daxor?

Daxor (NASDAQ:DXR) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

1.3% of Daxor shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Titan Medical has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$10.30M	5.92	N/A	N/A	N/A
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30

In the previous week, Daxor had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for Daxor and 0 mentions for Titan Medical. Daxor's average media sentiment score of 1.89 beat Titan Medical's score of 0.00 indicating that Daxor is being referred to more favorably in the media.

Company	Overall Sentiment
Daxor	Very Positive
Titan Medical	Neutral

Daxor's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Titan Medical	N/A	-82.31%	-51.47%

Daxor has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summary

Daxor beats Titan Medical on 9 of the 11 factors compared between the two stocks.

How does Titan Medical compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Titan Medical has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. Titan Medical's return on equity of -82.31% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Titan Medical	N/A	-82.31%	-51.47%

Nyxoah has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Titan Medical has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$15.33M	3.54	-$101.92M	-$2.48	N/A
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30

In the previous week, Nyxoah had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for Nyxoah and 0 mentions for Titan Medical. Nyxoah's average media sentiment score of 1.87 beat Titan Medical's score of 0.00 indicating that Nyxoah is being referred to more favorably in the media.

Company	Overall Sentiment
Nyxoah	Very Positive
Titan Medical	Neutral

0.0% of Titan Medical shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nyxoah presently has a consensus target price of $5.96, indicating a potential upside of 325.89%. Given Nyxoah's stronger consensus rating and higher probable upside, equities analysts plainly believe Nyxoah is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nyxoah and Titan Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does Titan Medical compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Pulmonx presently has a consensus target price of $5.58, suggesting a potential upside of 377.21%. Given Pulmonx's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pulmonx is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Pulmonx had 3 more articles in the media than Titan Medical. MarketBeat recorded 3 mentions for Pulmonx and 0 mentions for Titan Medical. Pulmonx's average media sentiment score of 0.62 beat Titan Medical's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Positive
Titan Medical	Neutral

Pulmonx has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Titan Medical has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$88.55M	0.56	-$54M	-$1.30	N/A
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30

Titan Medical has a net margin of 0.00% compared to Pulmonx's net margin of -60.09%. Titan Medical's return on equity of -82.31% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Titan Medical	N/A	-82.31%	-51.47%

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Pulmonx beats Titan Medical on 9 of the 16 factors compared between the two stocks.

How does Titan Medical compare to Spectral AI?

Titan Medical (NASDAQ:TMDIF) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Spectral AI has a consensus target price of $4.00, suggesting a potential upside of 143.90%. Given Spectral AI's stronger consensus rating and higher possible upside, analysts clearly believe Spectral AI is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Titan Medical has a net margin of 0.00% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Spectral AI	-85.58%	N/A	-72.97%

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 13.7% of Spectral AI shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Spectral AI had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for Spectral AI and 0 mentions for Titan Medical. Spectral AI's average media sentiment score of 0.94 beat Titan Medical's score of 0.00 indicating that Spectral AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Spectral AI	Positive

Titan Medical has higher earnings, but lower revenue than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30
Spectral AI	$19.65M	2.66	-$7.57M	-$0.53	N/A

Summary

Spectral AI beats Titan Medical on 10 of the 16 factors compared between the two stocks.

Get Titan Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDIF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDIF vs. The Competition

Export

Metric	Titan Medical	Surgical & medical instruments Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.12M	$41.50M	$6.87B	$12.26B
Dividend Yield	N/A	1.08%	2.67%	9.79%
P/E Ratio	-0.09	17.83	27.14	23.64
Price / Sales	0.74	28.68	517.06	88.99
Price / Cash	0.02	18.86	50.54	59.64
Price / Book	0.11	8.49	10.28	6.07
Net Income	$6.95M	-$16.99M	$3.60B	$331.99M
7 Day Performance	-27.17%	-4.36%	-1.27%	-0.63%
1 Month Performance	-28.86%	-2.71%	-0.37%	-2.00%
1 Year Performance	-68.95%	-19.38%	18.30%	13.62%

Titan Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDIF Titan Medical	N/A	$0.12 -13.0%	N/A	-66.1%	$13.12M	$17.63M	N/A	50	Gap Down
LNSR LENSAR	1.6828 of 5 stars	$5.75 -0.9%	$10.00 +73.9%	-56.7%	$70.61M	$58.44M	N/A	110	Positive News
DXR Daxor	1.6728 of 5 stars	$11.12 +2.0%	N/A	+4.5%	$64.91M	N/A	N/A	37	Positive News High Trading Volume
NYXH Nyxoah	3.3024 of 5 stars	$1.57 -0.3%	$5.96 +281.0%	-82.0%	$60.66M	$11.33M	N/A	110	Positive News
LUNG Pulmonx	3.584 of 5 stars	$1.37 -2.5%	$5.58 +309.0%	-64.8%	$57.66M	$90.50M	N/A	250	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDIF) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Titan Medical (TMDIF) Competitors

TMDIF vs. LNSR, DXR, NYXH, LUNG, and MDAI

How does Titan Medical compare to LENSAR?

Summary

How does Titan Medical compare to Daxor?

Summary

How does Titan Medical compare to Nyxoah?

Summary

How does Titan Medical compare to Pulmonx?

Summary

How does Titan Medical compare to Spectral AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Titan Medical (TMDIF) Competitors

TMDIF vs. LNSR, DXR, NYXH, LUNG, and MDAI

How does Titan Medical compare to LENSAR?

Which has more risk and volatility, LNSR or TMDIF?

Does the media refer more to LNSR or TMDIF?

Do analysts recommend LNSR or TMDIF?

Which has preferable earnings and valuation, LNSR or TMDIF?

Do institutionals and insiders believe in LNSR or TMDIF?

Is LNSR or TMDIF more profitable?

Summary

How does Titan Medical compare to Daxor?

Do insiders & institutionals have more ownership in DXR or TMDIF?

Do analysts recommend DXR or TMDIF?

Which has preferable valuation & earnings, DXR or TMDIF?

Does the media favor DXR or TMDIF?

Is DXR or TMDIF more profitable?

Which has more volatility & risk, DXR or TMDIF?

Summary

How does Titan Medical compare to Nyxoah?

Is NYXH or TMDIF more profitable?

Which has more risk & volatility, NYXH or TMDIF?

Which has better valuation & earnings, NYXH or TMDIF?

Does the media refer more to NYXH or TMDIF?

Do institutionals and insiders have more ownership in NYXH or TMDIF?

Do analysts rate NYXH or TMDIF?

Summary

How does Titan Medical compare to Pulmonx?

Do analysts rate LUNG or TMDIF?

Does the media refer more to LUNG or TMDIF?

Which has more volatility & risk, LUNG or TMDIF?

Which has better valuation and earnings, LUNG or TMDIF?

Is LUNG or TMDIF more profitable?

Do insiders and institutionals believe in LUNG or TMDIF?

Summary

How does Titan Medical compare to Spectral AI?

Do analysts prefer TMDIF or MDAI?

Which has more volatility & risk, TMDIF or MDAI?

Is TMDIF or MDAI more profitable?

Do insiders & institutionals hold more shares of TMDIF or MDAI?

Does the media prefer TMDIF or MDAI?

Which has stronger valuation & earnings, TMDIF or MDAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools